Geode Capital Management’s Eterna Therapeutics ERNA Stock Holding History

Geode Capital Management’s Portfolio ERNA Stock Details ERNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$48.6K	Buy	9,778 +8,833	+935%	+$141K	﹤0.01%	4321
2025 Q4	$28.3K	Buy	945 +127	+16%	+$4.33K	﹤0.01%	4338
2025 Q3	$22.4K	Buy	818 +15	+2%	+$595	﹤0.01%	4405
2025 Q2	$36.9K	Buy	803 +21	+3%	+$1.51K	﹤0.01%	4273
2025 Q1	$52.2K	Buy	782 +96	+14%	+$11.8K	﹤0.01%	4191
2024 Q4	$75.7K	Buy	686 +632	+1,170%	+$171K	﹤0.01%	4165
2024 Q3	$21.5K	Sell	54 -9	-14%	-$5.76K	﹤0.01%	4390
2024 Q2	$43K	Buy	63 +3	+5%	+$2.26K	﹤0.01%	4309
2024 Q1	$53.8K	Hold	60	–	–	﹤0.01%	4301
2023 Q4	$40.3K	Hold	60	–	–	﹤0.01%	4404
2023 Q3	$50.9K	Buy	60 +23	+62%	+$21.2K	﹤0.01%	4416
2023 Q2	$30.4K	Hold	37	–	–	﹤0.01%	4597
2023 Q1	$48.9K	Hold	37	–	–	﹤0.01%	4524
2022 Q4	$45K	Buy	37 +4	+12%	+$5.64K	﹤0.01%	4618
2022 Q3	$60K	Hold	33	–	–	﹤0.01%	4722
2022 Q2	$126K	Sell	33 -28	-46%	-$201K	﹤0.01%	4492
2022 Q1	$943K	Sell	61 -2	-3%	-$37.9K	﹤0.01%	3644
2021 Q4	$1.96M	Buy	63 +6	+11%	+$326K	﹤0.01%	3374
2021 Q3	$4M	Buy	57 +9	+19%	+$777K	﹤0.01%	3042
2021 Q2	$6.44M	Buy	48 +47	+4,700%	+$6.77M	﹤0.01%	2751
2021 Q1	$39K	Hold	1	–	–	﹤0.01%	4420
2020 Q4	$47K	Hold	1	–	–	﹤0.01%	4176
2020 Q3	$36K	Hold	1	–	–	﹤0.01%	4064
2020 Q2	$46K	Hold	1	–	–	﹤0.01%	3985
2020 Q1	$32K	Hold	1	–	–	﹤0.01%	3984
2019 Q4	$46K	Hold	1	–	–	﹤0.01%	4098
2019 Q3	$71K	Hold	1	–	–	﹤0.01%	4011
2019 Q2	$80K	Hold	1	–	–	﹤0.01%	3999
2019 Q1	$85K	Hold	1	–	–	﹤0.01%	3929
2018 Q4	$41K	Hold	1	–	–	﹤0.01%	4020
2018 Q3	$94K	Hold	1	–	–	﹤0.01%	3941
2018 Q2	$94K	Hold	1	–	–	﹤0.01%	3878
2018 Q1	$144K	Hold	1	–	–	﹤0.01%	3770
2017 Q4	$89K	Hold	1	–	–	﹤0.01%	3845
2017 Q3	$129K	Hold	1	–	–	﹤0.01%	3772
2017 Q2	$144K	Hold	1	–	–	﹤0.01%	3774
2017 Q1	$182K	Hold	1	–	–	﹤0.01%	3691
2016 Q4	$180K	Hold	1	–	–	﹤0.01%	3648
2016 Q3	$144K	Hold	1	–	–	﹤0.01%	3703
2016 Q2	$182K	Sell	1 -1	-50%	-$113K	﹤0.01%	3622
2016 Q1	$193	Hold	2	–	–	﹤0.01%	3647
2015 Q4	$205K	Hold	2	–	–	﹤0.01%	3677
2015 Q3	$401K	Buy	+2	New	+$338K	﹤0.01%	3324
2015 Q2	–	Hold	0	–	–	–	3947
2015 Q1	–	Hold	0	–	–	–	3919
2014 Q4	–	Hold	0	–	–	–	3947
2014 Q3	–	Hold	0	–	–	–	3905
2014 Q2	–	Hold	0	–	–	–	3816
2014 Q1	–	Hold	0	–	–	–	3788
2013 Q4	–	Hold	0	–	–	–	3729
2013 Q3	–	Hold	0	–	–	–	3639
2013 Q2	–	Hold	0	–	–	–	3590

Other funds holding ERNA

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management's ERNA Position: Q1 2026 in Review

Geode Capital Management increased its Eterna Therapeutics (ERNA) stake by 935% in Q1 2026, buying an estimated $141K and bringing the position to 9,778 shares worth $48.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4321.

Geode Capital Management first reported a position in ERNA in Q3 2015 and has held it in 43 quarters since. The position peaked at $6.44M in Q2 2021. 15 funds tracked by Wall St. Rank hold ERNA as of Q1 2026.

Geode Capital Management held 9,778 shares of Eterna Therapeutics worth $48.6K as of Q1 2026.
Geode Capital Management bought 8,833 Eterna Therapeutics shares in Q1 2026, an estimated $141K.
Eterna Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4321 holding.
Geode Capital Management first reported a position in Eterna Therapeutics in Q3 2015 and has held it in 43 quarters since.
Geode Capital Management's Eterna Therapeutics position peaked at $6.44M in Q2 2021.
15 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.